Publicado Mar 4, 2014



PLUMX
Almetrics
 
Dimensions
 

Google Scholar
 
Search GoogleScholar
Descargas


Jairo Alejandro Aldana Bitar

David Santacruz Pacheco

Manuel Eliseo Urina Triana

##plugins.themes.bootstrap3.article.details##

Resumen

La reperfusión es el tratamiento definitivo para salvar miocardio isquémico del infarto. Un determinante principal del tamaño del infarto es la duración de la isquemia. El restablecimiento temprano de flujo sanguíneo al miocardio isquémico reduce los límites del tamaño del infarto y la mortalidad. De manera paradójica, el retorno del flujo sanguíneo al miocardio isquémico puede resultar en lesiones adicionales en el área de riesgo. Esta condición se conoce como lesión por reperfusión, y el daño es más probable que suceda cuando la terapia de reperfusión se retrasa. Incluso cuando la mayoría de los ensayos clínicos diseñados para evaluar agentes para prevenir la lesión por reperfusión han sido decepcionantes, terapias para limitar la lesión por reperfusión siguen siendo un área de investigación activa.

Keywords

Myocardial reperfusion therapies, ischaemic myocardium, reperfusion injury, terapias de reperfusión miocárdica, isquemia miocárdica, lesión por reperfusión,

References
1. Yellon D, Hausenloy D. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-35.
2. Ruiz M, García D. Fisiopatología del daño miocárdico por isquemia-reperfusión: nuevas oportunidades terapéuticas en el infarto agudo de miocardio. Rev Esp Cardiol. 2009; 62(2):199-209.
3. Jennings RB, Murry CE, Steenbergen C Jr, Reimer KA. Development of cell injury in sustained acute ischemia. Circulation. 1990;82:II2–II12.
4. Xu Y, Huo Y, Toufektsian MC, et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol. 2006;290:H692–H699.
5. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002;105: 656-62.
6. Bialik S, Cryns VL, Drincic A, et al. The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ Res. 1999;85:403-14.
7. Saraste A, Pulkki K, Kallajoki M, et al. Apoptosis in human acute myocardial infarction. Circulation. 1997;95:320-23.
8. Talukder MA, Zweier JL, Periasamy M. Targeting calcium transport in ischaemic heart disease. Cardiovasc Res. 2009;84:345-52.
9. Zimmerman ANE, Daems W, Hulsmann WC, et al. Morphological changes of heart muscle caused by successive perfusion with calcium-free and calciumcontaining solutions (calcium paradox). Cardiovasc Res. 1967;1:201–9.
10. Turer A, Hill J. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol. 2010;106(3):360-68.
11. Zweier, J, Talukder, M. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res. 2006;70:181-90.
12. Penna C, Bassino E, Alloatti G. Platelet activating factor: the good and the bad in the ischemic/reperfused heart. Exp Biol Med. 2011;236:390-401.
13. Schulza R, Kelmb M, Heusch G. Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc Res. 2004;61:402-13.
14. Eefting F, Rensing B, Wigman J, et al. Role of apoptosis in reperfusion injury. Cardiovascular Research. 2004;61:414-26.
15. Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T, Levine B, Sadoshima J. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res. 2007;100:914-22.
16. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res. 2004;61:481-97.
17. Akar FG, Aon MA, Tomaselli GF, O‘Rourke B. The mitochondrial origin of postischemic arrhythmias. J Clin Invest. 2005;115:3527-35.
18. Iliceto S, Galiuto L, Marchese A, et al. Analysis of microvascular integrity, contractile reserve, and myocardial viability after acute myocardial infarction by dobutamine echocardiography and myocardial contrast echocardiography. Am J Cardiol. 1996;77:441-5.
19. Hoffmann R, Haager P, Lepper W, et al. Relation of coronary flow pattern to myocardial blush grade in patients with first acute myocardial infarction. Heart. 2003;89:1147-51.
20. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344: 1895-903.
21. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 1998;98:2695-701.
22. de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in STelevation myocardial infarction. Observations from the TIMI 14 trial. Circulation. 2000;101: 239-43.
23. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 2003;42:1879-85.
24. Iliceto S, Galiuto L, Marchese A, et al. Functional role of microvascular integrity in patients with infarct-related artery patency after acute myocardial infarction. Eur Heart J. 1997;18:618-24.
25. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the ‘no reflow’ phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93:223-28.
26. Sabia PJ, Powers ER, Ragosta M, et al. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med. 1992;327:1825-31.
27. Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation. 1998;97:795-804.
28. Arai M, Lefer DJ, So T, et al. An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. J Am Coll Cardiol. 1996;27:1278-85.
29. Hearse DJ. Ischemia, reperfusion, and the determinants of tissue injury. Cardiovasc Drugs Ther. 1990;Suppl 4:767-76.
30. Ferrari R, Hearse DJ. Reperfusion Injury: Does It Exist and Does It Have Clinical Relevance? J Thromb Thrombolysis. 1997;4:25-34.
31. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. J Am Coll Cardiol. 1999;34:1711-20.
32. Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J. 2006;27:2400-5.
33. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000;101:2154-9.
34. Kopecky SL, Aviles RJ, Bell MR, et al. A randomized, double-blinded, placebocontrolled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J. 2003;146:146-52.
35. Ishihara M, Sato H, Tateishi H, et al. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J. 1996;132:959-63.
36. Van Gilst, WH, Kingma, JH. Protection of the myocardium against postischemic reperfusion damage: possible role of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 1992;19:S13-9.
37. Piana RN, Wang SY, Friedman M, Sellke FW. Angiotensin-converting enzyme inhibition preserves endothelium-dependent coronary microvascular responses during short-term ischemia-reperfusion. Circulation. 1996;93:544-51.
38. Wang QD, Li XS, Lundberg JM, Pernow J. Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovasc Res. 1995;29:805-12.
39. Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res. 1993;27:1613-18.
40. Pernow J, Wang QD. Endothelin in myocardial ischaemia and reperfusion. Cardiovasc Res. 1997;33: 518-26.
41. Galiuto L, DeMaria AN, del Balzo, U, et al. Endothelin A-antagonist reduces no-reflow and infarct size in dogs. J Am Coll Cardiol. 1999;Special Issue (Suppl):382A.
42. Klein HH, Pich S, Bohle RM, et al. Myocardial protection by Na(+)-H+ exchange inhibition in ischemic, reperfused porcine hearts. Circulation. 1995;92:912-7.
43. Meng HP, Maddaford TG, Pierce GN. Effect of amiloride and selected analogues on postischemic recovery of cardiac contractile function. Am J Physiol. 1993;264:H1831-5.
44. Hendrikx M, Mubagwa K, Verdonck F, et al. New Na(+)-H+ exchange inhibitor HOE 694 improves postischemic function and high-energy phosphate resynthesis and reduces Ca2+ overload in isolated perfused rabbit heart. Circulation. 1994;89:2787-98.
45. Rohmann S, Weygandt H, Minck KO. Preischaemic as well as postischaemic application of a Na+/H+ exchange inhibitor reduces infarct size in pigs. Cardiovasc Res. 1995;30:945-51.
46. Coletta AP, Cleland JG. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail. 2001;3:747-50.
47. Zeymer U, Suryapranata H, Monassier JP, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol. 2001;38:1644-50.
48. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904-10.
49. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92 Suppl 4:iv6-14.
50. Hale, SL, Leeka, JA, Kloner, RA. Improved Left Ventricular Function and Reduced Necrosis after Myocardial Ischemia/Reperfusion in Rabbits Treated with Ranolazine, an Inhibitor of the Late Sodium Channel. J Pharmacol Exp Ther. 2006;318:418-23.
51. Sakata Y, Kodama K, Ishikura F, et al. Disappearance of the ‘no-reflow’ phenomenon after adjunctive intracoronary administration of nicorandil in a patient with acute myocardial infarction. Jpn Circ J. 1997;61:455-8.
52. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999;33:654-60.
53. Krombach GA, Higgins CB, Chujo M, Saeed M. Gadomer-enhanced MR imaging in the detection of microvascular obstruction: alleviation with nicorandil therapy. Radiology. 2005;236:510-8.
54. Sodi-Pallares D, Testelli MR, Fishleder BL, et al. Effects of an intravenous infusion of a potassium–glucose–insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol. 1962;9:166–81.
55. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose–insulin–potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE ECLA trial. JAMA. 2005;293: 437–46.
56. Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation. 2001;104:2778-83.
57. Gonon AT, Gourine AV, Middelveld RJ, et al. Limitation of infarct size and attenuation of myeloperoxidase activity by an endothelin A receptor antagonist following ischaemia and reperfusion. Basic Res Cardiol. 2001;96:454-62.
58. Harlan JM, Winn RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med. 2002;30:S214-9.
59. Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003;108:1176-83.
60. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003;108:1184-90.
61. Armstrong PW, Granger CB, et al. APEX AMI Investigators. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007; 297:43-51.
62. Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;45:1406-12.
63. Hanlon PR, Fu P, Wright GL, et al. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J. 2005;19:1323-25.
64. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol. 2005;100:397-403.
65. Xu B, Dong GH, Liu H, et al. Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappaB. Ann Clin Lab Sci. 2005;35: 161-8.
66. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther. 2005;19:33-40.
67. Jeanes HL, Wanikiat P, Sharif I, Gray GA. Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury. Menopause. 2006;13:80-6.
68. Sbarouni E, Iliodromitis EK, Bofilis E, et al. Estrogen alone or combined with edroxyprogesterone but not raloxifene reduce myocardial infarct size. Eur J Pharmacol. 2003;467:163-8.
69. Liu X, Pachori AS, Ward CA, et al. Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. FASEB J. 2006;20:207-16.
70. Jung F, Palmer LA, Zhou N, Johns RA. Hypoxic regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac myocytes. Circ Res. 2000;86:319-25.
71. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995; 345:669-82.
72. Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomized controlled trial. Lancet. 2002;360:1189-96.
73. Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res. 2003;60:617-25.
74. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359: 473-81.
75. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003; 285:H579-88.
76. Argaud L, Gateau-Roesch O, Raisky O, et al. Postconditioning inhibits mitochondrial permeability transition. Circulation. 2005;111: 194-7.
77. Zhao ZQ, Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res. 2006;70:200-11.
78. Loukogeorgakis SP, Panagiotidou AT, Yellon DM, et al. Postconditioning protects against endothelial ischemia-reperfusion injury in the human forearm. Circulation. 2006;113:1015-9.
79. Tsang A, Hausenloy DJ, Yellon DM. Myocardial postconditioning: reperfusion injury revisited. Am J Physiol Heart Circ Physiol. 2005; 289:H2-7.
80. Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study. Catheter Cardiovasc Interv. 2005;65:361-7.
81. Vinten-Johansen J, Yellon DM, Opie LH. Postconditioning: a simple, clinically applicable procedure to improve revascularization in acute myocardial infarction. Circulation. 2005;112:2085-88.
82. Dixon SR, Whitbourn RJ, Dae MW, et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol. 2002;40:1928-34.
83. Ly HQ, Denault A, Dupuis J, et al. A pilot study: the Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (the NICAMI Study). Am Heart J. 2005;150:933.
84. Kandzari DE, Chu A, Brodie BR, et al. Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study). Am J Cardiol. 2004;93:636-39.
Cómo citar
Aldana Bitar, J. A., Santacruz Pacheco, D., & Urina Triana, M. E. (2014). Síndrome de lesión por reperfusión miocárdica. Universitas Medica, 55(2), 166-182. https://doi.org/10.11144/Javeriana.umed55-2.slrm
Sección
Artículos de revisión

Artículos más leídos del mismo autor/a